Teva, the world’s largest maker of generic drugs, emphasized the strength of its pipeline at a meeting for investors and analysts. CEO Israel Makov said he was very happy with the company’s current performance having enjoyed a year which saw it launch generic versions of cholesterol treatments Zocor and Pravachol and anti-depressant Zoloft.
However, Mr Makov added that the company is “multi-dimensional” and has a stable of experimental treatments for multiple sclerosis and auto-immune diseases, neurology and oncology.
The company is seeking to prove to regulators that Parkinson’s disease drug Azilect can slow the progression of the disease as well as treat it. With such an approved use, the drug’s annual sales could surpass $1 billion.